Brief Title
Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Official Title
A Phase I/II Clinical Trial of Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin
Brief Summary
The purpose of this Phase I study is to test the safety of different doses of specially
prepared immune cells (called "T cells") collected from blood. The Investigators want to find
a safe dose of these modified T cells for patients who have malignant pleural disease. They
want to find out what effects these T cells have on the patient and the cancer (MPD).
Phase 2 part of the study, the investigators will test the dose in combination with another
drug, pembrolizumab, to see what effects the study treatment has on malignant pleural
mesothelioma.
Detailed Description
This is an open-label, dose-escalating, non randomized, single-center, phase I/II study of
mesothelin-targeted T cells administered intrapleurally as an infusion in patients with a
diagnosis (histologically or cytologically documented) of MPD from mesothelioma, lung cancer,
or breast cancer. Patients receiving pembrolizumab in cohort 9 only includes patients with a
diagnosis of mesothelioma. The total number of patients studied will depend on the number of
dose levels tested, up to a maximum dose of 6×10^7 mesothelin-targeted T cells/kg or until
the maximum tolerated dose (MTD) is reached. In Phase I of this study, we anticipate infusing
a minimum of 4 and a maximum of 54 evaluable patients. The total number of enrolled patients
in Phase II of this study depends on the number of observed responses and ranges from 13-21
evaluable patients, including 6 patients treated at the final dose in Phase I.
For patients who were treated and were removed from study, duplicate enrollment is permitted
if it is determined the patients could receive benefit. If the patients meet all eligibility
criteria, they may receive treatment in a higher dose level cohort. Patients who are
re-treated with CAR T cell therapy will not be considered new accruals. Outcomes of
re-treated patients will be analyzed separately.
Patients may receive palliative radiotherapy for symptom management prior to or following the
CAR T cell infusion. If a patient receives palliative radiotherapy, the study PI, treating
Radiation Oncologist, and treating Medical Oncologist will decide whether to proceed with the
infusion. Palliative radiotherapy must be completed at least 2 days prior to the
administration of cyclophosphamide.
Patients in cohort 9 and in the Phase II portion of the study will begin treatment with
pembrolizumab 4 weeks (+3/-1 week window) after completing CAR T cell administration.
Patients will receive 3 doses of pembrolizumab given on a recurring schedule followed by
reassessment. Patients responding or deriving clinical benefit, without unacceptable
toxicity, will be followed for up to 6 months after the first dose of pembrolizumab and may
continue pembrolizumab. Patients who cannot receive all 6 doses of pembrolizumab at MSK will
be followed and medical records including images will be obtained from the treating
physician.
Study Phase
Phase 1/Phase 2
Study Type
Interventional
Primary Outcome
Composite measure of severity and number of adverse events (AEs); changes in (clinical laboratory test findings (hematologic and chemistry); and physical examination. (Phase I)
Secondary Outcome
Changes in serum levels of the biomarker soluble mesothelin related peptide (SMRP) (Phase I)
Condition
Malignant Pleural Disease
Intervention
iCasp9M28z T cell infusions
Study Arms / Comparison Groups
modified T cells alone (without chemotherapy)
Description: Following enrollment, leukapheresis product will be obtained in the blood donor facility at MSKCC and cryopreserved in the Cell Therapy and Cell Engineering Facility (CTCEF). Before protocol treatment, the leukapheresis product will be thawed, and T cell isolation, transduction, and expansion of iCasp928z T cells will be performed in the MSKCC CTCEF Facility. It is estimated that it will take approximately 3 to 6 weeks to generate T cells for treatment.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Genetic
Estimated Enrollment
179
Start Date
May 2015
Completion Date
April 2021
Primary Completion Date
April 2021
Eligibility Criteria
Inclusion Criteria:
- Patients with MPD aged ≥18 years
- Karnofsky performance status ≥70%
- Patients with malignant pleural disease (MPD), pathologically confirmed at MSKCC
(radiographic confirmation is acceptable for screening phase eligibility), and defined
as one of the following (patients who have not yet received treatment may enroll in
the screening portion only):
1. Malignant pleural mesothelioma - previously treated with at least one prior
treatment regimen.
2. Non-small cell lung cancer metastatic to the pleura-previously treated with at
least one prior treatment regimen (chemotherapy or targeted agent) and documented
progression of disease. Patients with disease outside of the pleura will be
discussed among study PI and Co-PIs prior to considered eligible for the study.
Disease outside of the pleura must not require any immediate therapy per PI's
discretion.
3. Breast cancer metastatic to the pleura- previously treated with at least one
prior treatment regimen (chemotherapy or targeted agent) and documented
progression of disease. Patients with disease outside of the pleura will be
discussed among study PI and Co-PIs prior to be considered eligible for the
study. Disease outside of the pleura must not require any immediate therapy per
PI's discretion.
- Only patients with a diagnosis of malignant pleural mesothelioma will be included in
cohort 9 and in the Phase II portion of the study
- Expression of mesothelin must be confirmed by meeting one of the following criteria.
1. Mesothelin expression (>10% of the tumor expressing mesothelin) by
immunohistochemical (IHC) analysis
2. Elevated serum SMRP levels (>1.0 nM/L).
- Free flowing pleural effusion requiring management by placement of a pleural catheter.
Patients with a functional pleural catheter already in place are eligible for the
study, as long as there are no clinical concerns of infection.
OR
- No free-flowing pleural effusion: an Interventional Radiologist has agreed that
radiology-guided intrapleural or peritumoral injection of the CAR T cells is feasible.
- Chemotherapy, targeted therapy (such as a tyrosine kinase inhibitor) or therapeutic
radiotherapy must have been completed at least 14 days prior to administration of T
cells. Continuation of hormonal therapy (ie for breast cancer) is acceptable. Prior
immunotherapy with checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or
CTL4-antagonist or similar agent) must have been completed more than 1 month1prior to
the T cell infusion.
- Chemotherapy must have been completed at least 7 days prior to leukapheresis
- Palliative radiotherapy must be completed at least 2 days prior to administration of
cyclophosphamide
- Any major thoracic (thoracotomy with lung or esophageal resection) or abdominal
(laparotomy with organ resection) operation must have occurred at least 28 days before
study enrollment. Patients who have undergone diagnostic VATS or laparoscopy can be
included in the study.
- All acute toxic effects of any previous therapeutic or palliative radiotherapy,
chemotherapy, or surgical procedures must have resolved to grade I or lower according
to CTCAE (version 4.0).
- Lab requirements (hematology)
- White blood cell (WBC) count ≥3000 cells/mm3
- Absolute neutrophil count ≥1500 neutrophils/mm3
- Platelet count ≥100,000 platelets/mm3 Lab requirements (serum chemistry)
- Bilirubin ≤ 1.5x upper limit of normal (ULN)
- Serum alanine aminotransferase and serum aspartate aminotransferase (ALT/AST) ≤.5x ULN
- Serum creatinine ≤ 1.5x ULN or Cr > 1.5x ULN, but calculated clearances of >60
- Negative screen for human immunodeficiency virus (HIV), hepatitis B virus (HBV)
antigen, and hepatitis C virus (HCV). If testing was performed during the previous 3
months, there is no need to repeat testing, as long as documentation of results is
provided to the study site. Subjects must receive counseling and sign a separate
informed consent form for HIV testing.
- Subjects and their partners with reproductive potential must agree to use an effective
form of contraception during the period of drug administration and for 4 weeks after
completion of the last administration of the study drug. An effective form of
contraception is defined as oral contraceptives plus 1 form of barrier or
double-barrier method contraception (condom with spermicide or condom with diaphragm).
- Subjects must be able to understand the potential risks and benefits of the study and
must be able to read and provide written, informed consent for the study
Exclusion Criteria:
- Untreated or active CNS metastases (progressing or requiring anticonvulsants or
corticosteroids for symptomatic control); patients with a history of treated CNS
metastases are eligible, provided that all of the following criteria are met:
- Presence of measurable or evaluable disease outside of the CNS;
- Radiographic demonstration of improvement upon completion of CNS-directed therapy
and no evidence of interim progression between completion of CNS-directed therapy
and the screening radiographic study;
- Completion of radiotherapy ≥8 weeks prior to the screening radiographic study;
- Discontinuation of corticosteroids and anticonvulsants ≥4 weeks prior to the
screening radiographic study.
- Non-small cell lung cancer metastatic to the pleura that extends outside of the pleura
requiring immediate therapy
- Breast cancer metastatic to the pleura that extends outside of the pleura requiring
immediate therapy
- Prior history of seizure disorder
- Patients currently receiving treatment for concurrent active malignancy Continuation
of hormonal therapy (i.e. for breast cancer) is acceptable. Prior immunotherapy with
checkpoint blockade (i.e. PD1 inhibitor, PDL1 inhibitor or CTL4-antagonist or similar
agent) must have been completed more than 1 month prior to the T cell infusion.
- Autoimmune or antibody-mediated disease, including but not limited to systemic lupus
erythematosus, rheumatoid arthritis, ulcerative colitis, Crohn's disease, and temporal
arteritis (Patients with a history of hypothyroidism will not be excluded)
- History of myocarditis or congestive heart failure (as defined by New York Heart
Association Functional Classification III or IV), as well as unstable angina, serious
uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction 6
months prior to study entry
- Subjects with left ventricular ejection fraction (LVEF) less than 50%
- Patients with active interstitial lung disease (ILD)/pneumonitis or a history of
ILD/pneumonitis requiring treatment with systemic steroids
- Baseline pulse oximetry is less than 92% on Room air
- Pregnant or lactating women
- An infection requiring antibiotic treatment within 7 days before the start of
treatment (day 0)
- A requirement for daily systemic corticosteroids for any reason or a requirement for
other immunosuppressive or immunomodulatory agents. Topical, nasal, and inhaled
steroids are permitted.
- Administration of live, attenuated vaccine within 8 weeks before the start of
treatment (day 0) and throughout the study
- Any other medical condition that, in the opinion of the PI, may interfere with a
subject's participation in or compliance with the study
Gender
All
Ages
18 Years - N/A
Accepts Healthy Volunteers
No
Contacts
Marjorie Zauderer, MD, 646-888-4656,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02414269
Organization ID
15-007
Responsible Party
Sponsor
Study Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
Bellicum Pharmaceuticals
Study Sponsor
Marjorie Zauderer, MD, Principal Investigator, Memorial Sloan Kettering Cancer Center
Verification Date
October 2020